Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.

By C. Hudis, W. Barlow, J. Costantino, R. Gray, K. Pritchard, J. W. Chapman, J. Sparano, S. Hunsberger, R. Enos, R. Gelber and 1 more. Journal of Clinical Oncology, 2007

789 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Statistics and Probability

View Paper: https://www.semanticscholar.org/paper/1c3cd08434441559505897baa589a94b8bf9c881

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. K. Pantel
2. C. Alix‐Panabières

In Oncology

1. Keith A. Baggerly
2. G. Hortobagyi
3. K. Pantel
4. C. Alix‐Panabières

In Statistics and Probability

1. Vesteinn Thorsson
2. Katherine A. Hoadley

Citations in the corpus

• Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes (2013, methodology): “We identified OS and DMFS from the diagnosis date to death or to diagnosis of distant metastasis (15).”
• Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. (2017, neutral): “9 72 (33) 79 (30) 109 (32) 260 (32) 23 (17) 28 (14) 31 (15) 342 (30) $ 30 71 (32) 96 (37) 151 (44) 318 (39) 19 (14) 40 (20) 37 (18) 414 (36) NA 4 (2) 3 (1) 9 (3) 16 (2) 67 (51) 1 (0) 1 (0) 85 (7) Diabetes No 195 (88) 236 (89) 293 (86) 724 (88) 95 (72) 93 (46) 84 (41) 996 (86) Yes 24 (12) 26 (10) 46 ”
• Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients (2014, methodology): “The endpoints were defined according to the STEEP criteria, with disease-free survival (DFS) as the primary endpoint (20).”
• An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics (2018, methodology): “Using OS or disease-specific survival (DSS) demands longer follow-up times; thus, in many clinical trials, disease-free interval (DFI) or progression-free interval (PFI) are used (Hudis et al., 2007; Punt et al., 2007; https://wiki.nci.nih.gov/plugins/ servlet/mobile#content/view/24279961).”
• Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration (2012, neutral): “The STandardized definitions for Efficacy End Points (STEEP) system [67] proposed standardized endpoint definitions for adjuvant breast cancer trials to address inconsistencies such as the fact that new primary tumors, non-cancer death and in situ cancers may or may not be included as events in DFS ”